Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 24, Issue 1, pp 65–66 | Cite as

Treatment of advanced malignant melanoma with coumarin and cimetidine: a pilot study

  • M. Ernest Marshall
  • Karen Butler
  • James Cantrell
  • Charles Wiseman
  • Lawrence Mendelsohn
Short Communication Coumarin, Cimetidine, Malignant Melanoma

Summary

Based on previous results demonstrating that coumarin and cimetidine render objective tumor regressions in renal cell carcinoma, we conducted a pilot study to determine whether these drugs posses activity against malignant melanoma. A total of 22 patients with advanced melanoma received 100 mg coumarin p.o. daily for 14 days; on day 15, cimetidine was added at an oral dose of 300 mg four times daily. Both drugs were continued until progression of disease. In all, 12 patients had previously been treated, but all patients had a favorable performance status. No response was observed in 19 patients. Two patients with a low tumor burden achieved a partial response and a third showed a minor response. There was no toxicity from this regimen. Although coumarin and cimetidine at this dose and schedule did not display significant activity in this study population, further studies are warranted to explore higher doses and focus on patients with relatively low tumor burdens.

Keywords

Carcinoma Melanoma Cell Carcinoma Cancer Research Pilot Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ahman D (1976) Nitrosoureas in the management of disseminated malignant melanoma. Cancer Treat Rep 60: 747Google Scholar
  2. 2.
    Camis R (1976) DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 60: 165Google Scholar
  3. 3.
    Flodgren P, Borgstrom S, Jonssen PE, Lindstrom C, Sjogren HO (1983) Metastatic malignant melanoma: regression induced by combined treatment with interferon [HuIFN- (Le)] and cimetidine. Int J Cancer 32: 657Google Scholar
  4. 4.
    Luce J (1972) Chemotherapy of malignant melanoma. Cancer 30: 1604Google Scholar
  5. 5.
    Marshall ME, Mendelsohn L, Butler K, Riley L, Cantrell J, Harvey J, Wiseman C, Taylor T, Macdonald JS (1987) Treatment of metastatic renal cell carcinoma with coumarin (1,2-benzopyrone) and cimetidine: a pilot study. J Clin Oncol 6: 862Google Scholar
  6. 6.
    Marshall ME, Conley D, Hollingsworth P, Brown S, Thompson IS (1988) Effects of coumarin (1,2-benzopyrone) on lymphocyte, natural killer cell and monocyte functions in vitro. J Biol Resp Mod 8: 70Google Scholar
  7. 7.
    Marshall ME, Riley LK, Rhoades J, Eicchorn T, Jennings CD, Cibull M, Thompson J (1988) Effects of coumarin (1, 2-benzopyrone) and cimetidine on peripheral blood lymphocytes, natural killer cells and monocytes in patients with advanced malignancies. J Biol Resp Mod 8: 62Google Scholar
  8. 8.
    McKelvey E (1977) bis-Chloroethylnitrosourea, vincristine, dimethyltriazeno-imidazole-carboxamide and chlorpromazine combination chemotherapy in disseminated malignant melanoma. Cancer 39: 5Google Scholar
  9. 9.
    Pedersen L, Rose C, Langvad E (1987) Combined treatment of advanced malignant melanoma with coumarin and cimetidine. A phase II study. Cancer Immunol Immunother 24: 178Google Scholar
  10. 10.
    Rosenberg SA, Lotze M, Muul L, Leitman S, Chang AE, Ettinghausen SE, Matory JL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New Engl J Med 313: 1485Google Scholar
  11. 11.
    Thornes RD (1983) Coumarin, melanoma, and cellular immunity. In: Protective agents in cancer. Academic Press, New York, p 43Google Scholar
  12. 12.
    Thornes RD, Lynch G (1983) Combination of cimetidine with other drugs for treatment of cancer. N Engl J Med 308: 591Google Scholar
  13. 13.
    Thornes RD, Lynch G, Sheehan MV (1982) Cimetidine and coumarin therapy of melanoma. Lancet II: 328Google Scholar
  14. 14.
    Tseng A Jr, Snyder J, Lee WMF, Kirsten E, Hakam A, McLick J, Buki J, Kun E (1987) Prevention of tumorigenesis of oncogene-transformed rat fibroblasts with DNA site inhibitors of poly (ADP ribose) polymerase. Proc Natl Acad Sci USA 84: 1107Google Scholar
  15. 15.
    Zanker KS, Blumel G, Lange J, Siewert JR (1984) Coumarin in melanoma patients: an experimental and clinical study. Drugs Exp Clin Res X: 767Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • M. Ernest Marshall
    • 3
  • Karen Butler
    • 3
  • James Cantrell
    • 1
  • Charles Wiseman
    • 2
  • Lawrence Mendelsohn
    • 3
  1. 1.St. Vincent's HospitalBirminghamUSA
  2. 2.Los AngelesUSA
  3. 3.Division of Hematology/OncologyUniversity of Kentucky Medical CenterLexingtonUSA

Personalised recommendations